AMRI to recruit more than 40 full-time chemists to work at Lilly’s Indianapolis headquarters
Albany, NY (November 7, 2011) — AMRI (NASDAQ: AMRI) announced today that, as part of a new... read more
Scott Bartz, a former Johnson & Johnson insider, says he knows why the unsolved Tylenol Murders case has confounded investigators for more than 29 years. He unravels this mystery in his new... read more
Four European patient groups have called for more and improved measures against the use of unlicensed and off-label medicines.
The European Alliance for Access to Safe Medicines (EAASM),... read more
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has said the industry plans to address the rise of non-communicable disease (NCDs), such as diabetes and... read more
by Tracy Weber and Charles Ornstein ProPublica, Sep. 16, 2011, 2:23 p.m.
This story was co-published with the Washington... read more
An expert in carotid artery stenting discusses the CREST trial, embolic protection device decisions,
and the importance of medical simulation technology in training the next... read more
Less than a week away, the Rodman & Renshaw 13th Annual Healthcare Conference from September 11-13th will showcase a host of small biotech companies presenting their products, trial data and... read more
Albany, NY (August 18, 2011) – AMRI (NASDAQ: AMRI) today announced it received a federal contract
award from the National Institutes of Health (NIH)/National Institute of Neurological... read more
Hypercholesterolemia Therapeutics Market is Forecast to Show Moderate Growth
The hypercholesterolemia therapeutics market is predicted to witness marginal growth by 2017... read more
By Jeffrey Ball
What does it take to make a great medical sales professional? That is the question that many marketing and sales organizations have contemplated. Yet, to many sales... read more
Westlake, Texas and Greeley, Colo. – March 14, 2011 – Animal Health International, Inc. (NASDAQ: AHII) and privately held Lextron, Inc. today announced that they have entered into a definitive... read more
It is happening already. Doctors are hearing about the Sunshine Act and shutting their doors to reps.
The problem? Pharmaceutical companies are beginning to disclose the names of physicians... read more
New study leads to important new insights into high risk coronary lesions for heart attacks. This may lead to routine studies beyond coronary angiography and may provide the basis for new... read more
Submit an article to cafepharma's CP Wire. Click here to find out more.